Scholar Rock (SRRK)
(Delayed Data from NSDQ)
$29.49 USD
-4.79 (-13.97%)
Updated Oct 8, 2024 04:00 PM ET
Pre-Market: $29.82 +0.33 (1.12%) 8:18 AM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$29.49 USD
-4.79 (-13.97%)
Updated Oct 8, 2024 04:00 PM ET
Pre-Market: $29.82 +0.33 (1.12%) 8:18 AM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Zacks News
SRRK Stock Soars as Muscle Disease Drug Meets Phase III Study Goal
by Zacks Equity Research
Scholar Rock stock skyrockets as the late-stage study of the investigational therapy, apitegromab, to treat spinal muscular atrophy meets the primary goal.
Wall Street Analysts See a 99.11% Upside in Scholar Rock Holding Corporation (SRRK): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 99.1% in Scholar Rock Holding Corporation (SRRK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why 'Trend' Investors Would Love Betting on Scholar Rock Holding Corporation (SRRK)
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Scholar Rock Holding Corporation (SRRK) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
All You Need to Know About Scholar Rock Holding Corporation (SRRK) Rating Upgrade to Strong Buy
by Zacks Equity Research
Scholar Rock Holding Corporation (SRRK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Think Scholar Rock Holding Corporation (SRRK) Could Surge 203.99%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 204% in Scholar Rock Holding Corporation (SRRK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Biotech Stock Roundup: ALDX, EVLO Down on Setback, SRRK Offers Updates & More
by Ekta Bagri
Regulatory and pipeline updates from Aldeyra Therapeutics (ALDX) and Scholar Rock (SRRK) are in focus in the biotech sector.
Scholar Rock (SRRK) Up on Pipeline Advancement, Stock Offering
by Zacks Equity Research
Scholar Rock (SRRK) rises on plans to advance SRK-439 for treating obesity and offering common stock.
Why You Should Bet on 4 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Scholar Rock (SRRK), PTK Acquisition (VLN), OI Glass (OI) and Sera Prognostics (SERA).
Wall Street Analysts Believe Scholar Rock Holding Corporation (SRRK) Could Rally 264.53%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Scholar Rock Holding Corporation (SRRK) points to a 264.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Amicus (FOLD) Q2 Earnings Beat, Galafold Sales Miss Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) posts a narrower-than-expected loss for the second quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.
Amarin (AMRN) Q2 Earnings & Sales Hurt by Vazkepa Generics
by Zacks Equity Research
Amarin's (AMRN) Vazkepa sales decline year over year amid rising generic competition and COVID-related disruptions during the second quarter. The company's stock witnesses a decline on Aug 3.
Repligen (RGEN) Q2 Earnings and Sales Beat Estimates, Stock Up
by Zacks Equity Research
Repligen (RGEN) reports encouraging second-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022
Ultragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up
by Zacks Equity Research
Ultragenyx (RARE) reports a wider-than-expected loss in the second quarter. Nevertheless, revenues marginally beat estimates.
Does Scholar Rock Holding Corporation (SRRK) Have the Potential to Rally 246% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 246.1% upside potential for Scholar Rock Holding Corporation (SRRK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Global Blood (GBT) Initiates Phase II Study on SCD Candidate
by Zacks Equity Research
Global Blood Therapeutics (GBT) initiates the phase II portion of its planned phase II/III studies on pipeline candidate GBT601 to identify the optimal dose for the pivotal phase III portion of the trial
BioMarin (BMRN) Gets CHMP Nod for Hemophilia Drug Roctavian
by Zacks Equity Research
BioMarin (BMRN) receives a positive CHMP opinion for Roctavian, its gene therapy for treating adults with hemophilia A. The European Commission's decision is expected by the third quarter of 2022.
How Much Upside is Left in Scholar Rock Holding Corporation (SRRK)? Wall Street Analysts Think 394%
by Zacks Equity Research
The consensus price target hints at a 394.4% upside potential for Scholar Rock Holding Corporation (SRRK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Think Scholar Rock Holding Corporation (SRRK) Could Surge 413%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Scholar Rock Holding Corporation (SRRK) points to a 412.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Down 43.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Scholar Rock Holding Corporation (SRRK)
by Zacks Equity Research
Scholar Rock Holding Corporation (SRRK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
ANI Pharmaceuticals (ANIP) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
ANI (ANIP) delivered earnings and revenue surprises of -250% and 1.56%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Calyxt (CLXT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Calyxt (CLXT) delivered earnings and revenue surprises of 22.22% and 96.24%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Scholar Rock Holding Corporation (SRRK) Stock Jumps 9.2%: Will It Continue to Soar?
by Zacks Equity Research
Scholar Rock Holding Corporation (SRRK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Scholar Rock Holding Corporation (SRRK) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of 6.73% and 4.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Scholar Rock Holding Corporation (SRRK) Q4 Earnings Expected to Decline
by Zacks Equity Research
Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of -20.00% and 24.18%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?